Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia

Chris Frei, David S. Burgess

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study compares the cost-effectiveness of the 4 most common empiric antimicrobial regimens used for the treatment of adults with community-acquired pneumonia (CAP) at a community health system during a 6-month period. Associations between initial antimicrobials and total hospital costs were determined. Cost-effectiveness ratios were determined by dividing the total hospital costs by the percent survival. A total of 415 patients met criteria for the Pneumonia Severity Index (PSI) risk class IV or V. Costs (adjusted for inflation) were as follows (median, 25th and 75th percentile): total hospital costs ($5,078 [$3,218-$8,144]), pharmacy costs ($753 [$455-$1,357]), and antibiotic costs ($139 [$82-$229]). The most favorable cost-effectiveness ratio was observed for patients who received levofloxacin monotherapy ($4,635 per life saved), followed by ceftriaxone plus a macrolide ($5,278), ceftriaxone monotherapy ($5,368), and ceftriaxone plus levofloxacin ($6,317). Among patients admitted to the medical floor for class IV or V CAP, empiric levofloxacin monotherapy was associated with greater cost-effectiveness than ceftriaxone monotherapy, ceftriaxone plus a macrolide, or ceftriaxone plus levofloxacin.

Original languageEnglish (US)
Pages (from-to)298-303
Number of pages6
JournalFormulary
Volume40
Issue number9
StatePublished - Sep 2005

Fingerprint

Ceftriaxone
Cost-Benefit Analysis
Pneumonia
Levofloxacin
Hospital Costs
Macrolides
Costs and Cost Analysis
Community Health Planning
Economic Inflation
Anti-Bacterial Agents
Survival

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia. / Frei, Chris; Burgess, David S.

In: Formulary, Vol. 40, No. 9, 09.2005, p. 298-303.

Research output: Contribution to journalArticle

Frei, Chris ; Burgess, David S. / Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia. In: Formulary. 2005 ; Vol. 40, No. 9. pp. 298-303.
@article{cf0bdf4bd7c647f9814b75ec11508d8e,
title = "Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia",
abstract = "This study compares the cost-effectiveness of the 4 most common empiric antimicrobial regimens used for the treatment of adults with community-acquired pneumonia (CAP) at a community health system during a 6-month period. Associations between initial antimicrobials and total hospital costs were determined. Cost-effectiveness ratios were determined by dividing the total hospital costs by the percent survival. A total of 415 patients met criteria for the Pneumonia Severity Index (PSI) risk class IV or V. Costs (adjusted for inflation) were as follows (median, 25th and 75th percentile): total hospital costs ($5,078 [$3,218-$8,144]), pharmacy costs ($753 [$455-$1,357]), and antibiotic costs ($139 [$82-$229]). The most favorable cost-effectiveness ratio was observed for patients who received levofloxacin monotherapy ($4,635 per life saved), followed by ceftriaxone plus a macrolide ($5,278), ceftriaxone monotherapy ($5,368), and ceftriaxone plus levofloxacin ($6,317). Among patients admitted to the medical floor for class IV or V CAP, empiric levofloxacin monotherapy was associated with greater cost-effectiveness than ceftriaxone monotherapy, ceftriaxone plus a macrolide, or ceftriaxone plus levofloxacin.",
author = "Chris Frei and Burgess, {David S.}",
year = "2005",
month = "9",
language = "English (US)",
volume = "40",
pages = "298--303",
journal = "Formulary",
issn = "1082-801X",
publisher = "Advanstar Communications",
number = "9",

}

TY - JOUR

T1 - Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia

AU - Frei, Chris

AU - Burgess, David S.

PY - 2005/9

Y1 - 2005/9

N2 - This study compares the cost-effectiveness of the 4 most common empiric antimicrobial regimens used for the treatment of adults with community-acquired pneumonia (CAP) at a community health system during a 6-month period. Associations between initial antimicrobials and total hospital costs were determined. Cost-effectiveness ratios were determined by dividing the total hospital costs by the percent survival. A total of 415 patients met criteria for the Pneumonia Severity Index (PSI) risk class IV or V. Costs (adjusted for inflation) were as follows (median, 25th and 75th percentile): total hospital costs ($5,078 [$3,218-$8,144]), pharmacy costs ($753 [$455-$1,357]), and antibiotic costs ($139 [$82-$229]). The most favorable cost-effectiveness ratio was observed for patients who received levofloxacin monotherapy ($4,635 per life saved), followed by ceftriaxone plus a macrolide ($5,278), ceftriaxone monotherapy ($5,368), and ceftriaxone plus levofloxacin ($6,317). Among patients admitted to the medical floor for class IV or V CAP, empiric levofloxacin monotherapy was associated with greater cost-effectiveness than ceftriaxone monotherapy, ceftriaxone plus a macrolide, or ceftriaxone plus levofloxacin.

AB - This study compares the cost-effectiveness of the 4 most common empiric antimicrobial regimens used for the treatment of adults with community-acquired pneumonia (CAP) at a community health system during a 6-month period. Associations between initial antimicrobials and total hospital costs were determined. Cost-effectiveness ratios were determined by dividing the total hospital costs by the percent survival. A total of 415 patients met criteria for the Pneumonia Severity Index (PSI) risk class IV or V. Costs (adjusted for inflation) were as follows (median, 25th and 75th percentile): total hospital costs ($5,078 [$3,218-$8,144]), pharmacy costs ($753 [$455-$1,357]), and antibiotic costs ($139 [$82-$229]). The most favorable cost-effectiveness ratio was observed for patients who received levofloxacin monotherapy ($4,635 per life saved), followed by ceftriaxone plus a macrolide ($5,278), ceftriaxone monotherapy ($5,368), and ceftriaxone plus levofloxacin ($6,317). Among patients admitted to the medical floor for class IV or V CAP, empiric levofloxacin monotherapy was associated with greater cost-effectiveness than ceftriaxone monotherapy, ceftriaxone plus a macrolide, or ceftriaxone plus levofloxacin.

UR - http://www.scopus.com/inward/record.url?scp=25444507947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444507947&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:25444507947

VL - 40

SP - 298

EP - 303

JO - Formulary

JF - Formulary

SN - 1082-801X

IS - 9

ER -